For almost a decade, treatment goals for acromegaly have been those recommended by an expert group—achievement of serum growth hormone (GH) levels <2.5 µg/l and age-adjusted, normal levels of insulin-like growth factor I (IGF-I). This Practice Point commentary discusses a meta-analysis by Holdaway et al. that investigated the relationship between mortality and levels of GH and IGF-I in patients with acromegaly. The findings of the study confirm that the current criteria are adequate in terms of mortality, and that the prognosis of acromegaly has improved in the past 20 years. This improvement may be related to the comparatively aggressive treatment of the disease and management of comorbidities. Changes in the methods used by clinicians to measure GH levels probably require new criteria to be adopted, as good control of acromegaly is now more adequately defined as serum GH levels <1 µg/l and age-adjusted normal levels of IGF-I.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Pituitary Open Access 23 November 2013
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Giustina A et al. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526–529
Holdaway IM et al. (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159: 89–95
Kauppinen-Makelin R et al. (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90: 4081–4086
Colao A et al. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102–152
Nachtigall L et al. (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93: 2035–2041
Maison P and Chanson P (2006) Less is more risky? Growth hormone and insulin-like growth factor I levels and cardiovascular risk. Nat Clin Pract Endocrinol Metab 2: 650–651
Cazabat L et al. (2008) Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary 11: 129–139
Philippe Chanson received consulting and lecture fees and grant/research support from Novartis, Ipsen and Pfizer. Patrick Maison declared no competing interests.
About this article
Cite this article
Chanson, P., Maison, P. Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?. Nat Rev Endocrinol 5, 70–71 (2009). https://doi.org/10.1038/ncpendmet1048
This article is cited by